Evidence map›Paper›PMID 40579032›Full record

ArticleIn vivo (Athens, Greece)

Effect of Zoledronic Acid Administration Timing on Metastatic Bone Tumors.

Manabu Watanabe, Hiroyuki Tsuchie, Hiroyuki Nagasawa, Michio Hongo, Yuji Kasukawa, Daisuke Kudo, Fumihito Kasama, Keita Oya, Takashi Kawaragi, Naohisa Miyakoshi

Abstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Manabu WatanabeDepartment of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan; mwatanabe@med.akita-u.ac.jp.
Hiroyuki TsuchieDepartment of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
Hiroyuki NagasawaDepartment of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
Michio HongoDepartment of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
Yuji KasukawaDepartment of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
Daisuke KudoDepartment of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
Fumihito KasamaDepartment of Orthopedic Surgery, Akita Kousei Medical Center, Akita, Japan.
Keita OyaDepartment of Orthopedic Surgery, Oomori Municipal Hospital, Akita, Japan.
Takashi KawaragiDepartment of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
Naohisa MiyakoshiDepartment of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimBreast cancer frequently metastasizes to the bone, reducing quality of life and survival. Zoledronic acid (ZA), is used to treat bone metastasis; however, differences in efficacy depending on the timing of administration are not clear. This study investigated the effects of different timing of ZA administration in a mouse model of breast cancer bone metastasis. MATERIALS AND

methodsE0771 cells (1.0×10

resultsFive weeks after tumor-cell administration, bone destruction rate was significantly lower in all groups compared to the control group (

conclusionThe earlier ZA was administered, the more strongly it suppressed bone destruction and tumor cell proliferation.

Indexed as

Bone Density Conservation AgentsBone NeoplasmsBreast NeoplasmsZoledronic AcidAnimalsCell Line, TumorDiphosphonatesDisease Models, AnimalDrug Administration ScheduleFemaleImidazolesMiceTumor BurdenX-Ray MicrotomographyBone Density Conservation AgentsDiphosphonatesImidazolesZoledronic Acidadministration timingBone metastasiszoledronic acid

Identifiers

PMID40579032
PMCPMC12223653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.